Advanced Proteome Therapeutics Announces Warrant Extension
Vancouver, British Columbia–(Newsfile Corp. – March 18, 2022) – Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) (“APC” or the “Company”) announces that, it has applied to the TSX Venture Exchange for approval to amend the expiration of certain outstanding warrants (the “Warrants“). The Warrants’ exercise price and original expiry date are detailed below. The Warrants expiry date is to be extended to September 30, 2022. The warrants to be amended do not include any warrants issued to finders or agents. No other terms of the warrants are to be amended and the exercise remains at $0.27.
| Original Exercise Price | Number Outstanding | Original Expiry Date |
| Warrants @ $0.27 | 3,091,000 | March 27, 2022 |
| Warrants @ $0.27 | 1,667,000 | April 5, 2022 |
| Warrants @ $0.27 | 2,559,073 | April 13, 2022 |
Holders of warrants will not receive an amended warrant certificate and will be required to submit their original warrant certificate in order to exercise warrants.
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
Paul Woodward
President and CEO
Tel: 604 690-3797
http://www.advancedproteome.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements.
This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/117349
